Clinical verification of the relationship between smoking and the immune microenvironment of breast cancer

Table 3 Comparison of clinicopathological features by subtype

Parameters	Intrinsic subtype		p value
Parameters	HER2-enriched breast cancer (n = 62)	Triple-negative breast cancer (n = 87)	p value
Age (years old)
≤ 56	26 (41.9%)	49 (56.3%)	0.085
> 56	36 (58.1%)	38 (43.7%)	0.085
Tumour size (mm)
≤ 27.6	30 (48.4%)	45 (51.7%)	0.690
> 27.6	32 (51.6%)	42 (48.3%)	0.690
Skin infiltration
Negative	54 (87.1%)	80 (92.0%)	0.335
Positive	8 (12.9%)	7 (8.0%)	0.335
Lymph node status
Negative	25 (40.3%)	26 (29.9%)	0.188
Positive	37 (59.7%)	61 (70.1%)	0.188
Ki67
Negative	14 (22.6%)	9 (10.3%)	0.042
Positive	48 (77.4%)	78 (89.7%)	0.042
ORR
Non-responders	1 (1.6%)	10 (11.5%)	0.023
Responders	61 (98.4%)	77 (88.5%)	0.023
pCR
Negative	26 (41.9%)	49 (56.3%)	0.085
Positive	36 (58.1%)	38 (43.7%)	0.085
Recurrence
Negative	55 (88.7%)	68 (78.2%)	0.096
Positive	7 (11.3%)	19 (21.8%)	0.096
TILs
Low	20 (32.3%)	38 (43.7%)	0.206
High	42 (67.7%)	49 (56.3%)	0.206
Pack-years
Low	40 (64.5%)	66 (75.9%)	0.134
High	22 (35.5%)	21 (24.1%)	0.134

HER human epidermal growth factor receptor, ORR objective response rate, pCR pathological complete response, TILs tumour-infiltrating lymphocytes

ISSN: 1479-5876